Promising lymphoma combo trial cut short after enrolling just 5 patients
NCT ID NCT05498220
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 29 times
Summary
This study tested a new mix of cancer drugs (PV-RGDP) for people with diffuse large B-cell lymphoma that came back or didn't get better after first treatment. The goal was to see if adding polatuzumab vedotin to standard chemo could improve response. Only 5 people took part before the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27514, United States
Conditions
Explore the condition pages connected to this study.